POLE and colorectal carcinoma: Although the co-existence of POLE mutation has been frequently observed in CRC patients with MSI-H (26, 27), currently no studies have reported the efficacy of immunotherapy-based systemic therapy in CRC patients with both MSI-H and POLE mutations.